NCT05325710 Assessment of Personalized Follow-up in Prevention of Type 2 Diabetes
| NCT ID | NCT05325710 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ramsay Générale de Santé |
| Condition | Diabete Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 230 participants |
| Start Date | 2022-03-20 |
| Primary Completion | 2028-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 230 participants in total. It began in 2022-03-20 with a primary completion date of 2028-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In France, the overall prevalence of diabetes was estimated at 5% of population in 2016, type 2 diabetes (T2DM) corresponding to 90% of cases. However, this figure is greatly underestimated,since it does not take into account people who are untreated or not diagnosed. However,it is estimated that 20 to 30% of adults with diabetes do not are not diagnosed. Conclusions presented during the annual meeting of the european Association for the Study of diabetes (EASD-Berlin) from 2019 suggest that signs precursors of the disease would be present up to 20 years before the diagnosis. The Diagnosis is usually made around 40-50 years. The main factor of risk of T2D is the lifestyle, in particular a diet too rich for a too sedentary daily life. From a medico-economic point of view, chronic pathologies (including diabetes) account for 60% of insurance expenditure illness even though they concern 35% of insured persons, i.e. 20 million patients. The average annual repayment of a type 2 diabetic patient is 4890 euros. This study is part of this context as the starting point a reflection on a different, coordinated management, to know a preventive rather than a curative approach.
Eligibility Criteria
Inclusion Criteria: * Patient, male or female, over the age of 18 * Patient with a FINDRISC score ≥10 points * Beneficiary of a French health insurance system * Patient having been informed and having given their consent free, enlightened and written Exclusion Criteria: * Patient over 75 years old * Patient already diagnosed with type 2 diabetes * Patient whose physical and/or psychological health is severely impaired, which according to the investigator may affect the compliance of the study participant. * Patient participating in another research * Patient in period of exclusion from another research always in progress at the time of inclusion. * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by court order or administration. * Pregnant, breastfeeding or parturient women. * Patient hospitalized without consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05325710 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Diabete Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05325710 currently recruiting?
Yes, NCT05325710 is actively recruiting participants. Contact the research team at jf.oudet@ecten.eu for enrollment information.
Where is the NCT05325710 trial being conducted?
This trial is being conducted at Biarritz, France.
Who is sponsoring the NCT05325710 clinical trial?
NCT05325710 is sponsored by Ramsay Générale de Santé. The trial plans to enroll 230 participants.